IGBA’s Newly Launched CEO Advisory Committee Holds Inaugural Meeting with WTO Director General

The newly established IGBA CEO Advisory Committee, a forum for generic and biosimilar medicines industry leaders to discuss broad, strategic issues, and to engage and position the industry on a range of critical policy matters, held its inaugural meeting on Monday, May 2 and launched initial discussions with World Trade Organization (WTO) Director-General Dr. Ngozi Okonjo-Iweala.

“During the discussions with Dr. Ngozi, members of IGBA’s new CEO Advisory Committee outlined the essential role of generic and biosimilar medicines in global patient care and the significant contribution of the industry during the COVID-19 pandemic,” commented Vivian Frittelli, Chair of the IGBA Management Committee.

“Members of the Advisory Committee welcomed the WTO’s efforts to promote barrier-free trade and protect a resilient global supply chain for medicines, and the importance of promoting a balanced approach to competition and innovation to enable patients to benefit from a competitive pharmaceutical marketplace” Frittelli said. “Achieving greater predictability is a critical underpinning of improved access to medicines, and this will be one area of focus for ongoing discussions and action with the WTO moving forward,” Vivian Frittelli concluded.

For more information: IGBA establishes a CEO Advisory Committee (February 2022)

About us: The International Generic and Biosimilar medicines Association (IGBA) strengthens cooperation between associations representing manufacturers of generic and biosimilar medicines from around the world. Adopting a patient centric approach, IGBA works to improve patients’ access to quality-assured, safe and cost-effective medicines by promoting competition and enabling innovation in the pharmaceutical sector and sustainable economic contributions for all stakeholders. For more details, regarding IGBA and its member associations, see the IGBA website at: www.igbamedicines.org

Add comment